NCT02735460

Brief Summary

Andago V2.0 is a recently developed overground gait and balance training device. Many patients in neurorehabilitation suffer from gait disorders, most typically after stroke. Since pharmacological therapies are basically not available, neurorehabilitation plays an important role in the treatment of such patients. The Andago V2.0 may represent a useful device in the rehabilitation of stroke and other neurological patients featuring a severe gait disorder. Therefore a study has been designed to investigate the usability of the Andago V2.0 in the setting of a neurorehabilitation clinic. The primary outcomes of this study are the usability and acceptance of the investigational medical device (IMD). Usability is mainly measured by the time spent for the set-up and release of the participant, achieved training times and distances, the number of stumbles, collisions and emergency stops and the error messages during the session. Besides patient and therapist satisfaction with the Andago V2.0 is recorded.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2016

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2016

Completed
14 days until next milestone

First Submitted

Initial submission to the registry

March 15, 2016

Completed
28 days until next milestone

First Posted

Study publicly available on registry

April 12, 2016

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 3, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 3, 2017

Completed
Last Updated

October 1, 2018

Status Verified

September 1, 2018

Enrollment Period

11 months

First QC Date

March 15, 2016

Last Update Submit

September 27, 2018

Conditions

Outcome Measures

Primary Outcomes (3)

  • Usability of the IMD according to the number of participants that are able to use the Andago V2.0

    3 weeks

  • Acceptance of the IMD as measured by a therapist satisfaction questionnaire

    3 weeks

  • Acceptance of the IMD as measured by a patient satisfaction questionnaire

    3 weeks

Study Arms (1)

Treatment arm

EXPERIMENTAL

In this arm the Andago V2.0 is used.

Device: Andago V2.0

Interventions

The Andago V2.0 is tested in 2 sessions, the first being a training session to define the probably optimal settings for the subsequent therapy session. In the therapy session the participant performs a specific parcours. Usually this parcours can be done within 10 minutes. However, the session is stopped as soon as the patient feels too exhausted or becomes too weary.

Treatment arm

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Informed consent as documented by signature
  • Primary diagnosis of cerebral infarction (ICD-10: I63.0-I63.9) or intracerebral haemorrhage (ICD-10: I61.0-I69.9) independent of its location, age or cause
  • Gait disorder defined by a category of 1 to 3 on the Functional Ambulation Classification (FAC) (17)
  • Age above 18 years
  • Admission to Rehaklinik Zihlschlacht for in-patient neurorehabilitation

You may not qualify if:

  • Inability of the participant to understand the informed consent or to follow the procedures of the study, e.g., due to language problems, psychiatric disorders, cognitive impairment or aphasia (item 9 of the National Institute of Health Stroke Scale (NIHSS) ≥2)
  • Weight \>135 kg
  • Height \>200 cm
  • Bone fragility (e.g., non-consolidated fractures or osteotomies including craniotomies, osteopenia, osteoporosis or symptoms or indices in the patient history that infer a higher risk of bone density reduction)
  • Unstable arthroplasty
  • Uncontrolled knee or ankle instability that would still pose a danger despite the Body Weight Support (BWS) (especially lateral instability)
  • Lack of head control
  • Joint contractures
  • Relevant differences in leg length
  • Skin lesions (including pressure sores or enteric stomata) in areas of contact with harness support or lower extremity loading (feet)
  • Relevant sensory impairment in the lower limbs and trunk, especially with reduced pain sensation
  • Recent history or significant risk of seizures
  • Relevant cardiovascular conditions, e.g., cardiac insufficiency and thoracotomy, uncontrolled orthostatic hypotension or other circulatory problems, vascular disorders of the lower limbs
  • Mechanical ventilation
  • Long-term infusions (e.g., baclofen pump, other intrathecal pumps)
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rehaklinik Zihlschlacht, Center for Neurological Rehabilitation

Zihlschlacht, Switzerland

Location

MeSH Terms

Conditions

Brain IschemiaIntracranial Hemorrhages

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesHemorrhagePathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Detlef Marks

    Rehaklinik Zihlschlacht

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 15, 2016

First Posted

April 12, 2016

Study Start

March 1, 2016

Primary Completion

February 3, 2017

Study Completion

February 3, 2017

Last Updated

October 1, 2018

Record last verified: 2018-09

Data Sharing

IPD Sharing
Will not share

Locations